HIMALAYA III期研究:曲美木单抗联合度伐利尤单抗治疗不可切除肝细胞癌的4年总生存更新
HIMALAYA III期研究纳入不可切除肝细胞癌初治患者,随机接受STRIDE方案、度伐利尤单抗单药或索拉非尼治疗。4年更新分析显示,STRIDE较索拉非尼持续改善总生存,36个月和48个月总生存率分别为30.7%对19.8%和25.2%对15.1%,未发现新的迟发性安全性信号。
要点
- STRIDE组较索拉非尼组总生存获益持续,风险比0.78(95%CI 0.67-0.92)。
- STRIDE组48个月总生存率25.2%,索拉非尼组为15.1%。
- STRIDE组未出现新的治疗相关严重不良事件,长期安全性可控。
核心结论
- STRIDE方案较索拉非尼持续显示长期总生存获益,且安全性特征可控。
研究设计与样本
- III期HIMALAYA研究(NCT03298451)纳入不可切除肝细胞癌且未接受过系统治疗的患者。
- 患者随机分配至STRIDE组(n=393)、度伐利尤单抗组(n=389)或索拉非尼组(n=389)。
- 本次更新数据截止日期为2023年1月23日,评估总生存和严重不良事件。
主要发现
- STRIDE组、度伐利尤单抗组和索拉非尼组的中位随访时间分别为49.12个月(95%CI 46.95-50.17个月)、48.46个月(95%CI 46.82-49.81个月)和47.31个月(95%CI 45.08-49.15个月)。
- STRIDE组对比索拉非尼组的总生存风险比为0.78(95%CI 0.67-0.92)。
- STRIDE组36个月总生存率为30.7%,索拉非尼组为19.8%。
- STRIDE组48个月总生存率为25.2%,索拉非尼组为15.1%。
- STRIDE组长期生存者(n=103)中57.3%(59/103)未报告后续抗癌治疗。
关键数值与推荐
- STRIDE组36个月总生存率30.7%,索拉非尼组19.8%。
- STRIDE组48个月总生存率25.2%,索拉非尼组15.1%。
- STRIDE组治疗相关严重不良事件发生率为17.5%(68/388),自主要分析以来无新增。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the phase III HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) versus sorafenib; durvalumab monotherapy was noninferior to sorafenib for OS. Results reported herein are from a 4-year updated OS analysis of HIMALAYA. PATIENTS AND METHODS: Participants with uHCC and no previous systemic treatment were randomized to STRIDE (n = 393), durvalumab (n = 389), or sorafenib (n = 389). The updated data cut-off was 23 January 2023. OS and serious adverse events (AEs) were assessed. Additionally, baseline characteristics and subsequent therapies were analyzed in long-term survivors (≥36 months beyond randomization). RESULTS: For STRIDE, durvalumab, and sorafenib, median [95% confidence interval (CI)] follow-up was 49.12 months (46.95-50.17 months), 48.46 months (46.82-49.81 months), and 47.31 months (45.08-49.15 months), respectively. OS hazard ratio (95% CI) for STRIDE versus sorafenib was 0.78 (0.67-0.92). The 36-month OS rate for STRIDE was 30.7% versus 19.8% for sorafenib. The 48-month OS rate remained higher for STRIDE at 25.2%, versus 15.1% for sorafenib. The long-term OS benefit of STRIDE was observed across clinically relevant subgroups and was further improved in participants who achieved disease control. Long-term survivors with STRIDE (n = 103) included participants across clinically relevant subgroups, and 57.3% (59/103) had no reported subsequent anticancer therapy. No new serious treatment-related AEs occurred with STRIDE from the primary analysis (17.5%; 68/388). Durvalumab maintained OS noninferiority to sorafenib and no late-onset safety signals were identified. CONCLUSIONS: These data represent the longest follow-up to date in phase III studies in uHCC. The unprecedented 3- and 4-year OS rates reinforce the sustained long-term OS benefit of STRIDE versus sorafenib. STRIDE maintained a tolerable yet differentiated safety profile from other current uHCC therapies. Results continue to support the long-term benefits of STRIDE in a diverse population, reflective of uHCC globally.
引用
- Sangro B, Chan SL, Kelley RK, et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024. PMID: 38382875. doi:10.1016/j.annonc.2024.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。